A detailed history of Brewin Dolphin LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Brewin Dolphin LTD holds 5,000 shares of ALNY stock, worth $1.23 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,000
Previous 5,000 -0.0%
Holding current value
$1.23 Million
Previous $816,000 10.66%
% of portfolio
0.04%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Nov 14, 2022

BUY
$159.56 - $209.29 $797,800 - $1.05 Million
5,000 New
5,000 $848,000
Q2 2021

Nov 09, 2023

SELL
$128.63 - $176.89 $514,520 - $707,560
-4,000 Reduced 49.11%
4,145 $703 Million
Q3 2020

Nov 09, 2023

BUY
$121.19 - $165.49 $115,130 - $157,215
950 Added 13.2%
8,145 $1.19 Billion
Q2 2020

Nov 09, 2023

SELL
$104.21 - $156.44 $104,210 - $156,440
-1,000 Reduced 12.2%
7,195 $1.07 Billion
Q1 2020

Nov 09, 2023

SELL
$93.12 - $133.99 $331,972 - $477,674
-3,565 Reduced 30.31%
8,195 $892 Million
Q2 2019

Nov 09, 2023

BUY
$65.86 - $92.79 $164,650 - $231,975
2,500 Added 27.0%
11,760 $853 Million
Q1 2019

Nov 09, 2023

BUY
$72.76 - $93.45 $36,380 - $46,725
500 Added 5.71%
9,260 $865 Million
Q4 2018

Nov 09, 2023

BUY
$62.67 - $88.33 $98,391 - $138,678
1,570 Added 21.84%
8,760 $639 Million
Q3 2018

Nov 09, 2023

BUY
$87.52 - $122.67 $437 - $613
5 Added 0.07%
7,190 $629 Million
Q2 2018

Nov 09, 2023

BUY
$88.31 - $107.8 $91,842 - $112,112
1,040 Added 16.92%
7,185 $708 Million
Q1 2018

Nov 09, 2023

BUY
$115.92 - $148.54 $74,768 - $95,808
645 Added 11.73%
6,145 $732 Million
Q4 2017

Nov 09, 2023

SELL
$114.49 - $139.98 $171,735 - $209,969
-1,500 Reduced 21.43%
5,500 $699 Million
Q3 2017

Nov 09, 2023

BUY
$72.53 - $118.27 $145,060 - $236,540
2,000
7,000 $822 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Brewin Dolphin LTD Portfolio

Follow Brewin Dolphin LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

News

Stay updated on Brewin Dolphin LTD with notifications on news.